Female Sexual Dysfunction - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 61 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Female Sexual Dysfunction - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Female Sexual Dysfunction - Pipeline Review, H2 2014', provides an overview of the Female Sexual Dysfunction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Female Sexual Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Female Sexual Dysfunction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Female Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Female Sexual Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Female Sexual Dysfunction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Female Sexual Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Female Sexual Dysfunction Overview 6
Therapeutics Development 7
Pipeline Products for Female Sexual Dysfunction - Overview 7
Pipeline Products for Female Sexual Dysfunction - Comparative Analysis 8
Female Sexual Dysfunction - Therapeutics under Development by Companies 9
Female Sexual Dysfunction - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Female Sexual Dysfunction - Products under Development by Companies 13
Female Sexual Dysfunction - Companies Involved in Therapeutics Development 14
Palatin Technologies, Inc. 14
M et P Pharma AG 15
ANI Pharmaceuticals, Inc. 16
EndoCeutics, Inc. 17
Female Sexual Dysfunction - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
testosterone - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
prasterone - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
bremelanotide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
(bupropion hydrochloride + trazodone hydrochloride) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TBS-2 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PL-6983 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
S1B-307 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
S1B-3006 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Next Generation Melanocortin Receptor IV Agonist - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Female Sexual Dysfunction - Recent Pipeline Updates 43
Female Sexual Dysfunction - Dormant Projects 50
Female Sexual Dysfunction - Discontinued Products 51
Female Sexual Dysfunction - Product Development Milestones 52
Featured News & Press Releases 52
May 28, 2014: Trimel Pharmaceuticals Announces Positive Phase II Results for Tefina 52
May 06, 2014: Palatin Technologies Presents at the American Psychiatric Association 52
Feb 24, 2014: Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder 53
Jan 14, 2014: Trimel Completes Enrollment of Tefina Ambulatory Study 54
Oct 28, 2013: Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial 55
Jun 03, 2013: Trimel Receives Decision In Connection With Tefina Arbitration 55
Mar 01, 2013: Palatin Technologies Presents Positive Data For Bremelanotide In Female Sexual Dysfunction 55
Nov 08, 2012: Palatin Technologies Reports Positive Results For Phase IIB Bremelanotide Female Sexual Dysfunction Trial 57
Oct 15, 2012: Trimel To Enroll 240 Patients In Phase II Ambulatory Trial Of Tefina 59
Sep 10, 2012: Palatin Technologies Announces Last Patient Completed Treatment In Phase IIB Bremelanotide Female Sexual Dysfunction Trial 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Number of Products under Development for Female Sexual Dysfunction, H2 2014 7
Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Female Sexual Dysfunction - Pipeline by Palatin Technologies, Inc., H2 2014 14
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H2 2014 15
Female Sexual Dysfunction - Pipeline by ANI Pharmaceuticals, Inc., H2 2014 16
Female Sexual Dysfunction - Pipeline by EndoCeutics, Inc., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Assessment by Combination Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Female Sexual Dysfunction Therapeutics - Recent Pipeline Updates, H2 2014 43
Female Sexual Dysfunction - Dormant Projects, H2 2014 50
Female Sexual Dysfunction - Discontinued Products, H2 2014 51